Pharmafocus Home
    
Keyword Search
Go News Archive Features Events Appointments Jobs Contact Us About Us
Latest Features ( May )
Should I stay or should I go?
There are no easy answers when it comes to timing a job move, says Tim Ewbank, but you can make yourself a more attractive candidate for that next job.(more)
Regional research still hampered by cross-border differences
In the age of the Euro-trial, patients are not well served by processes that add unnecessary delays to the development of new medicines, says Les Rose(more)
A sea of paperwork or business as usual?
Steven Gray looks ahead to the soon-to-be finalised 2008 ABPI Code of Practice and how it will affect everyday practice in the UK industry(more)
PharmafocusNews Register for New Alert
News for July 2007
Previous Months: April 2008 |  March 2008 |  February 2008 |  January 2008 |  December 2007 |  November 2007 |  October 2007 |  September 2007 |  August 2007 |  July 2007 |  June 2007 |  May 2007 |  April 2007 |  March 2007 |  February 2007 |  January 2007 |  December 2006 |  November 2006 |  October 2006 |  September 2006 |  August 2006 |  July 2006 |  June 2006 |  May 2006 |  April 2006 |  March 2006 |  February 2006 |  January 2006 |  December 2005 |  November 2005 |  October 2005 |  September 2005 |  August 2005 |  July 2005 |  June 2005 |  May 2005 |  April 2005 |  March 2005 |  February 2005 |  January 2005 |  December 2004 |  November 2004 |  October 2004 |  September 2004 |  August 2004 |  July 2004 |  June 2004 |  May 2004 |  April 2004 |  March 2004 |  February 2004 |  January 2004 |  December 2003 |  November 2003 |  October 2003 |  September 2003 |  August 2003 |  July 2003 |  June 2003 |  May 2003 |  April 2003 |  March 2003 |  February 2003 |  January 2003 |  December 2002 |  November 2002 | 

  What is RSS?

Johnson defends NHS reform plans to MPs
But rules out further structural reorganisation and political independence..(more)

 Avandia safety scare costs GSK $200m
But revenues boosted by 12% growth in Seretide/Advair..(more)

 GSK's Cervarix gets European green light
Vaccine now must prove itself against Sanofi rival Gardasil..(more)

 Renewed push for private sector to challenge traditional GPs
PCTs to provide local action plans to improve access to services..(more)

 Latest news from Datamonitor
Product roundup in Alzheimer's, CNS, thrombosis, cancer and lupus..(more)

 Lilly expands UK research lab
Facility extension confirms company's commitment to the UK..(more)

 Spending pushes Actelion into loss but boom continues
Half-yearly figures disguise underlying rapid growth rate..(more)

 Roche splits top roles
Schwan becomes CEO as Humer steps down to concentrate on chairman role..(more)

 Lipitor woes take toll on Pfizer
Blockbuster patent expiries and R&D costs lead to 20% profit drop..(more)

 Woman wins court battle for Avastin treatment
Judgment represents further challenge to NICE's cost-effectiveness rulings..(more)

 The gloves come off for ABPI and NHS fight
The ABPIs challenge to NHS over prescribing controls set for the High Court..(more)

 Doctors free to overrule NICE decisions, claims charity
Concession in Alzheimer's judicial review exposes 'loophole' in NICE guidance..(more)

 Doctors defy NICE as Alzheimer's spending rises
Greater drug awareness after NICE draft guidance leads to increased prescribing..(more)

 Generic pressure curbs Novartis growth
But company has six strong products in approval/launch..(more)

 Newly merged Bayer Schering launched in the UK
Merger completed, Bayer Schering looks to key UK market challenges, including Nexavar access..(more)

 A guarded yes to Gardasil - and a door open to Cervarix
Delayed decision hangs on cost-effectiveness data and gives government bargaining power ..(more)

 Latest news from Datamonitor
Product roundup in cancer, pain and diabetes..(more)

 Independent PR agency Chandler Chicco acquired
$65m deal agreed with US marketing group inVentiv..(more)

 Radical revamp of NHS in London proposed
Polyclinic recommendations not well received..(more)

 FDA approves first Alzheimer's patch
Skin patch delivers Novartis' Exelon over course of 24 hours..(more)

 Janssen's Invega approved in Europe
Drug is first oral, prolonged-release antipsychotic to reach the market..(more)

 Piramed and Domainex named among best of British biotech
Companies recognised at awards ceremony for innovation and entrepreneurship ..(more)

 NICE reverses decision on Alimta
New data and appeals from Lilly and patient groups give access to mesothelioma treatment ..(more)

 Latest news from Datamonitor
Company and product news roundup ..(more)

 Moore's Sicko documentary launched in US
Moore's 'prescription for change' provokes anger from healthcare industries..(more)

 Dementia services failing patients, says watchdog
National Audit Office pinpoints diagnosis and early treatment as areas in need of improvement ..(more)

 Roche launches $3 billion hostile takeover bid for diagnostics company
Ventana acquisition would lead to important commmerical/clinical tie-in for Herceptin ..(more)

 Surgeon appointed to lead new NHS review
Clinician's appointment aims to heal rift between NHS staff and politicians ..(more)

 Advertising world celebrates the Best of Health
Paling Walters pick up a Best in Show and a Gold, but the night belongs to Woolley Pau..(more)

 ABPI launches legal challenge to prescribing controls
Generic medicines and payments to doctors come into the industry body's firing line..(more)

 Onyx to promote UCB narcolepsy drug
Media campaign will focus on raising narcolepsy awareness..(more)

 Roche strengthens autoimmune franchise with arthritis drug deal
Licence with Toyama Chemical could net company $370m plus royalties..(more)

 Alzheimer's sufferers wait for judgment as NICE put in dock
End in sight for two-year battle over drug access ..(more)

 Latest news from Datamonitor
News roundup in cancer, hypertension and stem cell research..(more)

 Prime Minister Brown appoints Alan Johnson Health Secretary
Johnson faces NHS problems of public disillusionment and low staff morale ..(more)

 GSK's leukaemia drug closer to European approval
GSK committed to orphan drug despite low numbers of patients..(more)

 Revlimid set for UK launch
But Celgene must convince the NHS the orphan drug gives value for money ..(more)

 FDA approves Lyrica for chronic pain condition
Further indication for Pfizer's epilepsy drug could bring in 6m extra patients..(more)

Are you a Pharmafocus subscriber?

Subscribe Now 

Visit our sister sites: 

InPharm.com 

Pharmafile.com 

Pharmafocus.com © 2006 Pharmafile Ltd.